Development of a Rhenium-186-Labeled MAG3-Conjugated Bisphosphonate for the Palliation of Metastatic Bone Pain Based on the Concept of Bifunctional Radiopharmaceuticals
- 1 July 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 16 (4) , 751-757
- https://doi.org/10.1021/bc040249w
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Studies on the Synthesis and Biological Properties of Non-Carrier-Added [125I and 131I]-Labeled Arylalkylidenebisphosphonates: Potent Bone-Seekers for Diagnosis and Therapy of Malignant Osseous LesionsJournal of Medicinal Chemistry, 2003
- Visualization of the Stomach on Rhenium-186 HEDP Imaging After Therapy for Metastasized Prostate CarcinomaClinical Nuclear Medicine, 1999
- Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response durationInternational Journal of Radiation Oncology*Biology*Physics, 1998
- 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labelingNuclear Medicine and Biology, 1998
- Osteolytic bone metastasis in breast cancerBreast Cancer Research and Treatment, 1994